What the Stanford study found
Published in Nature Medicine in January 2024, the study followed 30 male US special-operations veterans, most with mild traumatic brain injury and blast exposure, treated at a clinic in Mexico under a protocol pairing ibogaine with intravenous magnesium (called MISTIC).[1] One month after a single dose, participants averaged reductions of about 88 percent in PTSD symptoms, 87 percent in depression and 81 percent in anxiety, alongside improved cognition and reduced suicidal ideation, with benefits sustained through the 30-day follow-up.[2] The magnesium was included specifically to blunt ibogaine's QT-prolonging effect, and no serious cardiac events were reported.Why the caveats are not fine print
This is the study the whole PTSD case rests on, so the limits matter. It was open-label with no placebo or control group, so expectation and the intensity of the experience cannot be separated from the drug's effect. It was 30 people, all from a specific population of special-operations veterans with combat TBI, which may not generalize to civilian PTSD. Depression and anxiety improvements were secondary outcomes, not the result of dedicated trials. This is why we grade it strong-early, not proven.Where the research is going
The momentum is real. Texas committed $50 million in December 2025 to the IMPACT trial studying ibogaine for PTSD, addiction and cognitive trauma, mandating inpatient care and cardiac monitoring.[3] A federal executive order in April 2026 directed faster psychedelic research and a Right-to-Try pathway.[4] These are the studies that could turn strong-early evidence into controlled proof, and until they report, the honest status is "promising, unproven."A caution about fabricated trials
Some clinic websites cite a "Stanford Phase II, 120 patients, 71 percent" result or a "JAMA, 200 veterans, 67 percent" study. We could not verify either, and they do not exist in the published literature. The only rigorously published human ibogaine study to date is the 30-person Stanford work above. Treat larger cited veteran trials with suspicion and ask for the citation.What this means for you
- For PTSD and TBI there is real early human evidence, which is more than most advertised uses have. It is still small and uncontrolled.
- The magnesium co-treatment is part of why the Stanford cohort had no cardiac events. Ask any clinic whether it follows a magnesium protocol.
- If you can access an approved clinical trial (the IMPACT program is standing up in Texas), that is the monitored, lower-cost path as it opens.
- Ask any clinic to cite its evidence. If it points to a 120 or 200-patient trial, ask for the reference, because those are not in the literature.
Sources
- Cherian et al., "Magnesium-ibogaine therapy in veterans with traumatic brain injuries," Nature Medicine, Jan 5 2024
- Stanford Medicine, "Ibogaine treatment reduced PTSD symptoms in veterans," Jan 2024
- UTMB Health, Texas $50M IMPACT ibogaine trial announcement, Dec 12 2025
- The White House, "Accelerating Medical Treatments for Serious Mental Illness," April 18 2026
Reviewed against primary literature and updated July 2026. This is information, not medical advice.